Carregant...
Which donor or graft source should you choose for the strongest GVL? Is there really any difference
Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3900021/ https://ncbi.nlm.nih.gov/pubmed/24309533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.beha.2013.10.010 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|